Progress In Egfr Gene Mutation Therapy And Targeted Therapy In Non-Small Cell Lung Cancer (NSCLC)

Lung cancer ranks first in cancer causing death worldwide.About 10-30%of non-small-cell lung cancer(NSCLC)have mutations in epidermal growth factor receptor(EGFR),and patients with EGFR mutations have an effect on EGFR.The efficacy of TKI is significantly more pronounced.At present,in patients with EGFR-mutated NSCLC,EGFR TKI molecular targeted therapy is the first line of treatment,and most patients with initial response inevitably develop resistance and progress.This article briefly reviews the progress of the generations of EGFR inhibitors,the mechanisms of drug resistance,and the current research directions.